Core Insights - Clarivate is experiencing a "positive inflection point" after meeting its full-year financial guidance for the first time since 2019, with nearly 2% organic annual contract value (ACV) growth and over $1 billion in adjusted EBITDA for 2025 [2][5][6] Financial Performance - For 2025, Clarivate reported nearly 2% organic ACV growth, improved organic recurring revenue mix to 88%, and generated over $1 billion in adjusted EBITDA along with $365 million in free cash flow [6][7] - Fourth-quarter revenue was $617 million, with full-year revenue totaling $2.455 billion, primarily influenced by inorganic changes due to divestitures [7] - Adjusted diluted EPS for the fourth quarter was $0.20, reflecting a $0.02 sequential increase, with operating cash flow of $160 million [8] AI Strategy - Clarivate is implementing an "Intelligence Amplified" strategy, focusing on AI assistants and workflow agents, with 97% of revenue derived from proprietary solutions enhanced by AI [2][3][9] - The company has launched 10 AI assistants and AI-native solutions, now utilized by over 4,000 institutions, and expects to release more than 10 additional AI solutions in the coming year [10][12] Business Segments - The Life Sciences & Healthcare (LS&H) business is under review for potential sale to enhance focus on Academia & Government (A&G) and Intellectual Property (IP) markets, although 2026 guidance assumes LS&H will be retained for the full year [4][16] - In A&G, the segment achieved 2% organic ACV growth despite funding challenges, with a shift towards a recurring revenue model [10] - The IP segment is undergoing a turnaround with new leadership and AI product launches, showing a 270 basis points year-over-year improvement in annuities revenue [11] Capital Allocation and Leverage - Clarivate's capital allocation strategy includes $225 million in share repurchases and $200 million in bond retirements, maintaining net leverage at approximately four times [14][15] - For 2026, the company aims for 2-3% organic ACV growth, margin expansion to nearly 43%, and a free cash flow target of approximately $400 million [3][17]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $617 million, bringing the full year total to $2.455 billion, with changes driven entirely by inorganic factors due to business disposals [15] - Full year net income improved by $436 million compared to the previous year, primarily due to the absence of non-cash impairment charges and lower income tax and interest expenses [15] - Adjusted diluted EPS increased by $0.02 sequentially to $0.20 [15] - Free cash flow for the full year reached $365 million, reflecting a 2% growth over the prior year [19] Business Line Data and Key Metrics Changes - The Academia and Government segment achieved 2% organic ACV growth, with 93% of revenue now from proprietary solutions [10] - The Intellectual Property business saw a 270 basis points year-over-year improvement in annuities revenue, indicating stronger execution [12] - Life Sciences & Healthcare reported significant adoption of AI solutions, with 11,000 global active users leveraging AI research assistants [12] Market Data and Key Metrics Changes - The company reported stable revenue retention rates of 93% and expects organic annual contract value growth of 2%-3% for 2026 [13][21] - The anticipated decline in revenue due to strategic disposals is expected to be approximately $100 million, with organic recurring revenue mix improving to between 88% and 90% [21][23] Company Strategy and Development Direction - The company is focusing on selling its Life Sciences & Healthcare business to enhance emphasis on the A&G and IP markets and strengthen its balance sheet [5][49] - The AI strategy is centered on leveraging proprietary data and domain expertise to enhance product offerings, with 97% of revenue derived from proprietary assets [6][42] - The company aims to maximize shareholder value through portfolio simplification and disciplined capital allocation [14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, expecting continued improvement in key financial metrics and organic growth acceleration supported by AI innovation [14][13] - The company acknowledges market concerns regarding AI disruption but believes its proprietary business model provides a significant competitive advantage [5][6] Other Important Information - The company has initiated a process to sell its Life Sciences & Healthcare segment, which is expected to create shareholder value and allow for a more focused operational execution across A&G and IP segments [5][49] - The company plans to continue investing in product innovation while also focusing on cost efficiencies to improve capital spending [27] Q&A Session Summary Question: Monetization model for subscriptions and AI products - Management confirmed that the subscription model is evolving, with a focus on upselling AI innovations and transitioning to more subscription-based products [32][33] Question: Revenue from proprietary data and tech-enabled workflows - Management clarified that 97% of revenue comes from proprietary data, with a significant portion from information services and enterprise software [42] Question: Considerations for selling Life Sciences and Healthcare business - The decision was based on the goal of creating shareholder value and focusing on the A&G and IP segments, which have synergies [48][49] Question: Strategic synergies between IP and A&G segments - Management highlighted the benefits of shared content and technology platforms between the two segments, which can enhance innovation and operational execution [53][56] Question: Returning the IP segment to organic revenue growth - Management expressed confidence in the IP segment's turnaround, citing strong assets and a focus on innovation and execution [60][62] Question: Capital allocation priorities - Management indicated a focus on deleveraging while also considering stock buybacks, emphasizing the attractive free cash flow yield [68][70] Question: Price realization and revenue growth composition - Management noted that improvements in ACV and recurring revenue growth are primarily driven by volume rather than price increases [72][75]

Summary of Clarivate Conference Call Company Overview - **Company**: Clarivate (NYSE: CLVT) - **Date of Conference**: November 19, 2025 Key Industry Insights - **Industry Focus**: Information services, particularly in academic, life sciences, and intellectual property (IP) sectors - **Core Technology**: Emphasis on proprietary data and AI integration Core Points and Arguments 1. **Generative AI Impact**: Clarivate views generative AI as an opportunity rather than a threat, leveraging its proprietary data that cannot be replicated by public AI systems [4][5][6] 2. **Proprietary Data**: The company emphasizes its unique data assets across segments, including bibliometric databases and proprietary analytics, which are deeply embedded in client workflows [5][6][7] 3. **AI Innovations**: Clarivate is actively deploying AI across its products, enhancing existing offerings and introducing new AI-driven products, such as RiskMark and Web of Science Research Intelligence [8][15] 4. **Investment Strategy**: Current capital spending is deemed adequate, with a focus on AI-driven product development and operational efficiencies expected to enhance margins in the future [11][12] 5. **Subscription Growth**: The company has increased its subscription revenue from 80% to 88% of organic revenue, with plans to reach 90% [16][18] 6. **Renewal Rates**: Improvement in renewal rates from 92% to 93% attributed to product investments and enhanced customer success initiatives [14][20] 7. **Market Growth Projections**: Clarivate anticipates growth in the ANG market at 3%-4%, with life sciences showing mid-single-digit growth potential [21][22][30] 8. **IP Market Recovery**: New patent filings increased by 5%, indicating a recovery in the IP market, which is expected to benefit Clarivate's annuity business [24][25] 9. **Competitive Positioning**: Clarivate maintains a unique market position with a comprehensive suite of products that competitors cannot match [26] Additional Important Insights - **Geographic Stability**: The company reports stable budgets across major geographies, with encouraging performance in North America [29] - **Life Sciences Transition**: The life sciences segment is transitioning towards a higher percentage of subscription revenue, currently at 85% [32] - **Cash Flow and Capital Allocation**: Clarivate has robust free cash flow generation, with balanced capital allocation strategies including stock repurchases and debt reduction [36][37] This summary encapsulates the key points discussed during the Clarivate conference call, highlighting the company's strategic focus on AI, proprietary data, and subscription growth while navigating market dynamics and competitive positioning.

Core Insights - Clarivate Plc has launched RiskMark, an AI-powered solution designed to help trademark professionals evaluate trademark risk and generate evidence-backed arguments efficiently [1][4] - RiskMark utilizes a vast database of 172.5 million trademark records and over 5 million global court and administrative records to assess similarity risk [2] - The solution employs generative and predictive AI to provide near-instant results on various aspects of trademark evaluation, enhancing decision-making speed and confidence [2] Company Overview - Clarivate is recognized as a leading global provider of transformative intelligence, offering data, insights, analytics, and expert services across multiple sectors including Intellectual Property [5] - The company aims to empower IP professionals with trustworthy AI-driven insights to assess risk and streamline the drafting process for trademark-related arguments [4]